[{"id":"sol-pe1","name":"Change in HbA1c from baseline at Week 26","type":"PRIMARY","unit":"%","results":[{"arm":"Summary","value":"Met primary endpoint vs placebo (specific reduction not yet disclosed)","p_value":null}],"timepoint":"Week 26","description":"HbA1c is a blood test measuring average blood sugar over 3 months. Lower is better for diabetics. A reduction of ≥1% is considered clinically meaningful. This measures how well elecoglipron controls blood sugar vs placebo."}]

OPEN QUESTIONS: 1. How does elecoglipron HbA1c reduction compare to semaglutide active comparator arm? 2. Weight loss in T2DM population? (typically less than obesity-only) 3. Which doses selected for Phase 3? 4. Hypoglycemia rates? INVESTMENT IMPLICATIONS: - Non-inferior to sema on HbA1c + better weight loss: Strong positioning - Significantly inferior to sema: Questions entire program - Key differentiator is convenience (no fasting) — even matching sema efficacy would be a win Source: ClinicalTrials.gov NCT06579105; AZN Q4:25 earnings Feb 10, 2026

Phase 2b dose-ranging study in T2DM with semaglutide active comparator to benchmark efficacy